MeiraGTx Holdings plc - 8-K Filing
MeiraGTx entered into a $375 million Royalty Note Purchase Agreement with investors managed by Oberland Capital on June 30, 2026. The deal includes an initial $100M purchase and up to five additional tranches tied to clinical milestones for AAV-hAQP1 and bota-vec therapies. Proceeds will be used for working capital and debt repayment. Separately, the company issued ~950k shares at $10.52/share in a private placement raising approximately $10 million with an option for up to $15M more. (Items: 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2, 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended)
Tickers: $MGTX